Inspire Corporate Bond ETF IBD
23.22 USD -0.08 (-0.34%)
At closeNov 10, 2026, 4:00 PM EST
23.22 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
23.16 Day range 23.24
22.50 52-week range 24.78
- YTD
- -4.05%
- 1 year
- -3.69%
News
investors.com How Did This Low-Growth Stock Sneak Into IBD Growth Screens? Rather than impressing with growth, Cincinnati, Ohio-based Cintas wins on scale and a dependable business.
youtube.com Meta's $1,000 Bull Case: How Muse AI Changes The Valuation Game | IBD Meta's rollout of its new Muse AI agent marks a pivotal moment for the tech giant. But investors are questioning whether the model will be a lucrative revenue driver or an expensive defensive move.
gurufocus.com SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
prnewswire.com SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI® (risankizumab) and…
zacks.com Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now? Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
gurufocus.com Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026 Celltrion to Present New Analyses of ZYMFENTRAÂ (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026PR NewswireJERSEY CITY, N.J., Oct. 11, 2
gurufocus.com New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease New SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
gurufocus.com New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026 New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026PR NewswireMILAN, Oct. 10, 2026MILAN, Oct. 10, 2026 /PRNewswire/ -- From Octo
seekingalpha.com Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential…
investors.com AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why. Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.
globenewswire.com Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p
prnewswire.com Inspire Corporate Bond Fund (IBD) Receives 5-star Overall Morningstar Rating™ Among 155 Corporate Bond Funds BOISE, Idaho, Aug. 25, 2026 /PRNewswire/ -- Inspire Investing is pleased to announce that the Inspire Corporate Bond ETF (NYSE: IBD) has been awarded a 5-star Overall Morningstar Rating™ for the…
zacks.com Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD? SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
zacks.com Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now? Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
youtube.com Beyond The Megacaps: What To Watch In Eli Lilly, Sandisk, SpaceX Earnings | IBD IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Eli Lilly, Sandisk and SpaceX. Check out our daily newsletter!
benzinga.com Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2 Oppenheimer on Thursday initiated coverage of Palisade Bio Inc. (NASDAQ:PALI) , saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease…
youtube.com Why The Anthropic-Pentagon Clash Matters For The Entire AI Tech Stack | IBD Is the federal government's clash with Anthropic a warning sign for the entire artificial intelligence ecosystem? Tech strategist and Georgetown adjunct law professor Emily Benson breaks down the…
247wallst.com One AI Cooling Stock Is 10% Off Highs. Why IBD Says the Setup ‘Doesn't Get Much Better' The AI buildout's real bottleneck is the steel, copper, and chilled water surrounding the GPUs.
zacks.com Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now? A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
prnewswire.com AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week® AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile,…
benzinga.com The Good Book In An ETF